From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Model parameter | Definition | Estimated value | Units | Source |
---|---|---|---|---|

\(\alpha_{im}\) | Activation rate of APCs |
1.161 × 10^{3} to 2.986 × 10^{3}
| Cells/day | [27, 28] |

\(b\) | Number of tumor cells, required for reaching half of the maximal APC activation rate |
3.704 × 10^{4} to 1.476 × 10^{5}
| Cells | [27,28,29] |

\(\mu_{APC}\) | Death rate of APCs | 0.2310 |
Day^{−1}
| [30, 31] |

\(a_{pem}\) | Maximum effect of pembrolizumab on activation of CD8+ T cells | \(1 \times 10\) to \(1 \times 10^{4}\) | – | Model simulations |

\(\alpha_{eff}\) | Activation rate of naïve antigen-specific CD8+ T cells | 0.8318 |
Day^{−1}
| [32] |

\(b_{pem}\) | Maximum effect of pembrolizumab on the exhaustion rate of CD8+ T cells | 0.9 | – | Model simulations |

\(\mu_{eff}\) | Death rate of Effector CD8+ T cells | 0.1777 |
Day^{−1}
| [33] |

\(\gamma_{mel}\) | Net growth rate of tumor cells | 0.003269 to 0.08664 |
Day^{−1}
| [34] |

\(\upsilon_{mel}\) | Innate death rate of tumor cells by effector CD8+ T cells | 0.1245 |
Day^{−1}
| [35,36,37] |

\(g\) | Number of tumor cells, at which the elimination rate reaches half of its maximal value |
2.019 × 10^{7} to 1 × 10^{8}
| Cells | [36, 38] |